HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across Wall Street.
In its Q2 results, HCA Healthcare, Inc. reported that revenue increased 8.7% year-over-year to $20.23 billion from $18.61 billion in Q2 2025. The firm's net income attributable to the company rose 2.8% to $1.69 billion, while diluted EPS increased 11.6% to $7.62 (or $7.59 on an adjusted basis). Adjusted EBITDA grew 4.6% to $4.027 billion compared to $3.849 billion in the prior-year period. Operational volume remained positive overall, with same-facility admissions up 2.5%, equivalent admissions up 2.7%, and emergency room visits rising 3.6%. However, same-facility inpatient surgeries dropped 2.3%, and outpatient surgeries fell 3.4%.
Despite the top-line expansion, management was forced to adjust its full-year 2026 outlook downward. The company now expects 2026 diluted EPS of $28.70 to $30.50 (down from $29.10 to $31.50) and Adjusted EBITDA of $15.40 billion to $16.10 billion (down from $15.55 billion to $16.45 billion), while narrowing revenue guidance to $77.00 billion to $79.50 billion.
The primary culprit was a policy-driven payer mix shift: an uptick in uninsured volume following Medicaid redeterminations and the lapse of health insurance exchange coverage wiped out roughly $400 million from Q2 pre-tax income. HCA now anticipates the full-year exchange-related drag to reach $1.00 billion to $1.20 billion, partially offset by $300 million to $500 million in net Medicaid Supplemental Payment Program benefits.
Following the report, ***** ysts swiftly adjusted their models. On July 28, Mizuho lowered its price target on HCA to $475 from $525 while keeping an Outperform rating, citing slower post-Q2 growth expectations. The same day, Morgan Stanley reduced its price target to $380 from $425 and maintained an Underweight rating. Morgan Stanley ***** yst noted that while lower guidance "puts numbers in a better place," core EBITDA performance was "disappointing," warning of a full valuation alongside a rising risk profile in payer mix.
#year #payer #guidance
In its Q2 results, HCA Healthcare, Inc. reported that revenue increased 8.7% year-over-year to $20.23 billion from $18.61 billion in Q2 2025. The firm's net income attributable to the company rose 2.8% to $1.69 billion, while diluted EPS increased 11.6% to $7.62 (or $7.59 on an adjusted basis). Adjusted EBITDA grew 4.6% to $4.027 billion compared to $3.849 billion in the prior-year period. Operational volume remained positive overall, with same-facility admissions up 2.5%, equivalent admissions up 2.7%, and emergency room visits rising 3.6%. However, same-facility inpatient surgeries dropped 2.3%, and outpatient surgeries fell 3.4%.
Despite the top-line expansion, management was forced to adjust its full-year 2026 outlook downward. The company now expects 2026 diluted EPS of $28.70 to $30.50 (down from $29.10 to $31.50) and Adjusted EBITDA of $15.40 billion to $16.10 billion (down from $15.55 billion to $16.45 billion), while narrowing revenue guidance to $77.00 billion to $79.50 billion.
The primary culprit was a policy-driven payer mix shift: an uptick in uninsured volume following Medicaid redeterminations and the lapse of health insurance exchange coverage wiped out roughly $400 million from Q2 pre-tax income. HCA now anticipates the full-year exchange-related drag to reach $1.00 billion to $1.20 billion, partially offset by $300 million to $500 million in net Medicaid Supplemental Payment Program benefits.
Following the report, ***** ysts swiftly adjusted their models. On July 28, Mizuho lowered its price target on HCA to $475 from $525 while keeping an Outperform rating, citing slower post-Q2 growth expectations. The same day, Morgan Stanley reduced its price target to $380 from $425 and maintained an Underweight rating. Morgan Stanley ***** yst noted that while lower guidance "puts numbers in a better place," core EBITDA performance was "disappointing," warning of a full valuation alongside a rising risk profile in payer mix.
#year #payer #guidance
2 months ago
